Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Deacon, CF; Danielson, P; Klarskov, L; Olesen, M; Holst, JJ
   Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs
   DIABETES
   
   C.F. Deacon et al., "Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs", DIABETES, 50(7), 2001, pp. 1588-1597
2. Vilsboll, T; Krarup, T; Deacon, CF; Madsbad, S; Holst, JJ
   Reduced postprandial concentrations of intact biologically active gluccagon-like peptide 1 in type 2 diabetic patients
   DIABETES
   
   T. Vilsboll et al., "Reduced postprandial concentrations of intact biologically active gluccagon-like peptide 1 in type 2 diabetic patients", DIABETES, 50(3), 2001, pp. 609-613
3. Meier, JJ; Huking, K; Holst, JJ; Deacon, CF; Schmiegel, WH; Nauck, MA
   Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes
   DIABETES
   
   J.J. Meier et al., "Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes", DIABETES, 50(11), 2001, pp. 2497-2504
4. Hartmann, B; Harr, MB; Jeppesen, PB; Wojdemann, M; Deacon, CF; Mortensen, PB; Holst, JJ
   In vivo and in vitro degradation of glucagon-like peptide-2 in humans
   JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
   
   B. Hartmann et al., "In vivo and in vitro degradation of glucagon-like peptide-2 in humans", J CLIN END, 85(8), 2000, pp. 2884-2888
5. Deacon, CF; Nauck, MA; Meier, J; Hucking, K; Holst, JJ
   Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide
   JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
   
   C.F. Deacon et al., "Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide", J CLIN END, 85(10), 2000, pp. 3575-3581
6. Deacon, CF; Holst, JJ; Carr, RD
   Glucagon-like peptide-1: A basis for new approaches to the management of diabetes
   DRUGS OF TODAY
   
   C.F. Deacon et al., "Glucagon-like peptide-1: A basis for new approaches to the management of diabetes", DRUGS TODAY, 35(3), 1999, pp. 159-170
7. Hansen, L; Deacon, CF; Orskov, C; Holst, JJ
   Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying theL cells of the porcine intestine
   ENDOCRINOLOGY
   
   L. Hansen et al., "Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying theL cells of the porcine intestine", ENDOCRINOL, 140(11), 1999, pp. 5356-5363
8. DEACON CF; KNUDSEN LB; MADSEN K; WIBERG FC; JACOBSEN O; HOLST JJ
   DIPEPTIDYL PEPTIDASE-IV RESISTANT ANALOGS OF GLUCAGON-LIKE PEPTIDE-1 WHICH HAVE EXTENDED METABOLIC STABILITY AND IMPROVED BIOLOGICAL-ACTIVITY
   Diabetologia
   
   C.F. Deacon et al., "DIPEPTIDYL PEPTIDASE-IV RESISTANT ANALOGS OF GLUCAGON-LIKE PEPTIDE-1 WHICH HAVE EXTENDED METABOLIC STABILITY AND IMPROVED BIOLOGICAL-ACTIVITY", Diabetologia, 41(3), 1998, pp. 271-278
9. DEACON CF; RIBEL U; ROED B; HOLM HBJ; HOLST JJ; CARR RD
   GLUCAGON-LIKE PEPTIDE-1 (9-36)AMIDE DOES NOT DESENSITIZE CONSCIOUS PIGS TO THE ANTI-HYPERGLYCEMIC ACTION OF GLP-1
   Diabetologia
   
   C.F. Deacon et al., "GLUCAGON-LIKE PEPTIDE-1 (9-36)AMIDE DOES NOT DESENSITIZE CONSCIOUS PIGS TO THE ANTI-HYPERGLYCEMIC ACTION OF GLP-1", Diabetologia, 41, 1998, pp. 72-72
10. DEACON CF; HUGHES TE; HOLST JJ
    DIPEPTIDYL-PEPTIDASE-IV INHIBITION POTENTIATES THE INSULINOTROPIC EFFECT OF GLUCAGON-LIKE PEPTIDE-1 IN THE ANESTHETIZED PIG
    Diabetes
    
    C.F. Deacon et al., "DIPEPTIDYL-PEPTIDASE-IV INHIBITION POTENTIATES THE INSULINOTROPIC EFFECT OF GLUCAGON-LIKE PEPTIDE-1 IN THE ANESTHETIZED PIG", Diabetes, 47(5), 1998, pp. 764-769
11. HOLST JJ; DEACON CF
    INHIBITION OF THE ACTIVITY OF DIPEPTIDYL-PEPTIDASE-IV AS A TREATMENT FOR TYPE-2 DIABETES
    Diabetes
    
    J.J. Holst e C.F. Deacon, "INHIBITION OF THE ACTIVITY OF DIPEPTIDYL-PEPTIDASE-IV AS A TREATMENT FOR TYPE-2 DIABETES", Diabetes, 47(11), 1998, pp. 1663-1670
12. HOLST JJ; HANSEN L; ORSKOV C; WOJDEMANN M; WETIERGREN A; DEACON CF
    GLP-1 (7-36AMIDE) IS TRANSFORMED BY DIPEPTIDYL PEPTIDASE-IV IN THE CAPILLARIES SUPPLYING THE L-CELLS INTO GLP-1 (9-36AMIDE), WHICH ANTAGONIZES THE GASTROINTESTINAL EFFECTS OF GLP-1
    Diabetes
    
    J.J. Holst et al., "GLP-1 (7-36AMIDE) IS TRANSFORMED BY DIPEPTIDYL PEPTIDASE-IV IN THE CAPILLARIES SUPPLYING THE L-CELLS INTO GLP-1 (9-36AMIDE), WHICH ANTAGONIZES THE GASTROINTESTINAL EFFECTS OF GLP-1", Diabetes, 47, 1998, pp. 115-115
13. DEACON CF; HUGHES TE; HOLST JJ
    DIPEPTIDYL PEPTIDASE-IV INHIBITION POTENTIATES THE INSULINOTROPIC EFFECT OF GLUCAGON-LIKE PEPTIDE-1
    Diabetes
    
    C.F. Deacon et al., "DIPEPTIDYL PEPTIDASE-IV INHIBITION POTENTIATES THE INSULINOTROPIC EFFECT OF GLUCAGON-LIKE PEPTIDE-1", Diabetes, 47, 1998, pp. 268-268
14. HOLST JJ; HANSEN L; DEACON CF
    THE GLP-1 RECEPTOR ANTAGONIST, GLP-1 (9-36AMIDE), IS A PRIMARY PRODUCT OF THE INTESTINAL L-CELL
    Diabetologia
    
    J.J. Holst et al., "THE GLP-1 RECEPTOR ANTAGONIST, GLP-1 (9-36AMIDE), IS A PRIMARY PRODUCT OF THE INTESTINAL L-CELL", Diabetologia, 40, 1997, pp. 98-98
15. DEACON CF; KNUDSEN LB; JOHANSEN NL; MADSEN K; HOLST JJ
    DIPEPTIDYL PEPTIDASE-IV RESISTANT ANALOGS OF GLUCAGON-LIKE PEPTIDE-1 - IN-VITRO AND IN-VIVO STUDIES
    Diabetologia
    
    C.F. Deacon et al., "DIPEPTIDYL PEPTIDASE-IV RESISTANT ANALOGS OF GLUCAGON-LIKE PEPTIDE-1 - IN-VITRO AND IN-VIVO STUDIES", Diabetologia, 40, 1997, pp. 492-492
16. PRIDAL L; DEACON CF; KIRK O; CHRISTENSEN JV; CARR RD; HOLST JJ
    GLUCAGON-LIKE PEPTIDE-1(7-37) HAS A LARGER VOLUME OF DISTRIBUTION THAN GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE IN DOGS AND IS DEGRADED MORE QUICKLY IN-VITRO BY DOG PLASMA
    European journal of drug metabolism and pharmacokinetics
    
    L. Pridal et al., "GLUCAGON-LIKE PEPTIDE-1(7-37) HAS A LARGER VOLUME OF DISTRIBUTION THAN GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE IN DOGS AND IS DEGRADED MORE QUICKLY IN-VITRO BY DOG PLASMA", European journal of drug metabolism and pharmacokinetics, 21(1), 1996, pp. 51-59
17. DEACON CF; PRIDAL L; KLARSKOV L; OLESEN M; HOLST JJ
    GLUCAGON-LIKE PEPTIDE-1 UNDERGOES DIFFERENTIAL TISSUE-SPECIFIC METABOLISM IN THE ANESTHETIZED PIG
    American journal of physiology: endocrinology and metabolism
    
    C.F. Deacon et al., "GLUCAGON-LIKE PEPTIDE-1 UNDERGOES DIFFERENTIAL TISSUE-SPECIFIC METABOLISM IN THE ANESTHETIZED PIG", American journal of physiology: endocrinology and metabolism, 34(3), 1996, pp. 458-464
18. DEACON CF; KELSTRUP M; KLARSKOV L; OLESEN M; HOLST JJ
    METABOLISM OF GLUCAGON IN THE ANESTHETIZED PIG
    Diabetes
    
    C.F. Deacon et al., "METABOLISM OF GLUCAGON IN THE ANESTHETIZED PIG", Diabetes, 45, 1996, pp. 1118-1118
19. DEACON CF; JOHNSEN AH; HOLST JJ
    DEGRADATION OF GLUCAGON-LIKE PEPTIDE-1 BY HUMAN PLASMA IN-VITRO YIELDS AN N-TERMINALLY TRUNCATED PEPTIDE THAT IS A MAJOR ENDOGENOUS METABOLITE IN-VIVO
    The Journal of clinical endocrinology and metabolism
    
    C.F. Deacon et al., "DEGRADATION OF GLUCAGON-LIKE PEPTIDE-1 BY HUMAN PLASMA IN-VITRO YIELDS AN N-TERMINALLY TRUNCATED PEPTIDE THAT IS A MAJOR ENDOGENOUS METABOLITE IN-VIVO", The Journal of clinical endocrinology and metabolism, 80(3), 1995, pp. 952-957
20. DEACON CF; JOHNSEN AH; HOLST JJ
    HUMAN COLON PRODUCES FULLY PROCESSED GLUCAGON-LIKE PEPTIDE-1 (7-36)AMIDE
    FEBS letters
    
    C.F. Deacon et al., "HUMAN COLON PRODUCES FULLY PROCESSED GLUCAGON-LIKE PEPTIDE-1 (7-36)AMIDE", FEBS letters, 372(2-3), 1995, pp. 269-272
21. DEACON CF; PRIDAL L; HOLST JJ
    DIFFERENTIAL ORGAN-SPECIFIC METABOLISM OF GLUCAGON-LIKE PEPTIDE-1 IN THE ANESTHETIZED PIG
    Diabetologia
    
    C.F. Deacon et al., "DIFFERENTIAL ORGAN-SPECIFIC METABOLISM OF GLUCAGON-LIKE PEPTIDE-1 IN THE ANESTHETIZED PIG", Diabetologia, 38, 1995, pp. 167-167
22. HOLST JJ; OLESEN KM; GUDMANDHOYER E; DEACON CF; HANSEN CP; JOHNSEN AH; MIHOLIC J; NAUCK M; QUALMANN C
    THE COLON AS A SOURCE FOR GLUCAGON-LIKE PEPTIDE-1 (GLP-1)
    Diabetologia
    
    J.J. Holst et al., "THE COLON AS A SOURCE FOR GLUCAGON-LIKE PEPTIDE-1 (GLP-1)", Diabetologia, 38, 1995, pp. 170-170
23. DEACON CF; NAUCK MA; TOFTNIELSEN M; PRIDAL L; WILLMS B; HOLST JJ
    BOTH SUBCUTANEOUSLY AND INTRAVENOUSLY ADMINISTERED GLUCAGON-LIKE PEPTIDE-I ARE RAPIDLY DEGRADED FROM THE NH2-TERMINUS IN TYPE-II DIABETIC-PATIENTS AND IN HEALTHY-SUBJECTS
    Diabetes
    
    C.F. Deacon et al., "BOTH SUBCUTANEOUSLY AND INTRAVENOUSLY ADMINISTERED GLUCAGON-LIKE PEPTIDE-I ARE RAPIDLY DEGRADED FROM THE NH2-TERMINUS IN TYPE-II DIABETIC-PATIENTS AND IN HEALTHY-SUBJECTS", Diabetes, 44(9), 1995, pp. 1126-1131
24. APTEL HBC; DEACON CF; HENDERSON IW
    ATRIAL-NATRIURETIC-PEPTIDE IN THE MILAN HYPERTENSIVE RAT AND THE MILAN NORMOTENSIVE RAT - PLASMA-CONCENTRATION AND BINDING TO RENAL GLOMERULI IN YOUNG, ADULT AND AGED RATS
    Journal of hypertension
    
    H.B.C. Aptel et al., "ATRIAL-NATRIURETIC-PEPTIDE IN THE MILAN HYPERTENSIVE RAT AND THE MILAN NORMOTENSIVE RAT - PLASMA-CONCENTRATION AND BINDING TO RENAL GLOMERULI IN YOUNG, ADULT AND AGED RATS", Journal of hypertension, 12(11), 1994, pp. 1209-1215
25. APTEL HBC; DEACON CF; HENDERSON IW
    INTERACTIONS OF ATRIAL-NATRIURETIC-PEPTIDE WITH A7R5 CELLS
    Biochemical and biophysical research communications
    
    H.B.C. Aptel et al., "INTERACTIONS OF ATRIAL-NATRIURETIC-PEPTIDE WITH A7R5 CELLS", Biochemical and biophysical research communications, 204(3), 1994, pp. 1286-1291